The antidepressant question: what SSRIs can and cannot do

Tony Robbins' appearance on Theo Von's podcast in 2025 produced a moment that went viral across social media — a self-help figure with 50 years of stage presence, publicly questioning whether the drugs millions of people take daily actually work. The segment landed in a cultural moment already primed for it. In the Telegram thread that surfaced the clip, Robbins' basic claim found broad resonance: that major meta-analyses, including work discussed in a 2022 Newsweek cover story and subsequent peer-reviewed reviews, had found selective serotonin reuptake inhibitors barely outperformed placebo for many patients. Whether the framing was precise or not, the underlying concern was real, and it connected to something that large portions of the prescribing public have quietly suspected.

That public suspicion has rarely been acknowledged in mainstream medical discourse. SSRIs — drugs including fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro) — have been the dominant treatment for depression since the early 1990s. Their introduction was genuinely transformative: fewer side effects than older tricyclic antidepressants, safer in overdose, and backed by clinical trials that showed meaningful symptom reduction. They became a pillar of psychiatric practice, prescribed to tens of millions of Americans annually. What the Robbins conversation exposed is that the empirical basis for that dominance has always been thinner than the prescribing volume implied.

What the major reviews actually found

The 2023 JAMA Psychiatry review cited in Robbins' discussion — and referenced across the Telegram posts that amplified the segment — examined the pooled results of trials submitted to the FDA during initial SSRI approvals. The finding at the centre of the debate is straightforward: for the average patient with depression, the improvement over placebo was small. That result was not new. Earlier meta-analyses had reached similar conclusions. What changed in 2023 was the transparency with which it was described in a high-impact clinical journal, using the full dataset rather than only published trials. Industry-funded trials tend to produce more favourable results than independent research, a pattern documented across the SSRI literature. The JAMA review added methodological force to observations that had been circulating in academic psychiatry for years.

The implications are specific. For severe depression — the population where the clinical stakes are highest — the drug-placebo difference was clinically meaningful. For mild to moderate symptoms, which represent the majority of prescriptions written in high-income countries, the evidence was considerably weaker. The Telegram posts paraphrasing Robbins cited these findings at face value; the underlying science, stripped of rhetorical packaging, supports a more nuanced reading: SSRIs work, but they work most clearly where the need is greatest, and the effect size for the broader patient population is modest.

The methodological critique and its limits

Critics of the SSRI evidence base raise legitimate methodological concerns. Early industry-funded trials were often designed in ways that maximised apparent drug efficacy — short duration, enriched enrollment of patients who had previously responded to the drug, placebo washout periods that disadvantaged the placebo arm. Publication bias means positive results are more likely to reach publication than negative ones, skewing the cumulative literature. Some researchers argue that the active component of the placebo used in many trials was not inert, potentially blunting the measured drug-placebo difference.

These critiques are real. They do not, however, amount to a finding that SSRIs are ineffective. Regulatory agencies including the FDA approved these drugs on the basis of trials that met their statutory standards — trials that required, in each case, a statistically significant drug-placebo difference. The fact that industry participated in trial funding does not automatically corrupt the signal, as independent re-analyses using FDA submission datasets have largely confirmed the approve-able signal while questioning its magnitude.

The strongest evidence for SSRI efficacy is in severe depression. This is where the treatment effect is most robust, and where withholding treatment would cause the most harm. For this group, the debate about meta-analysis effect sizes is largely beside the point. The JAMA review does not contradict this clinical consensus; it complicates the extrapolation from that group to the much larger population with milder symptoms.

The Robbins framing and its audience

Robbins' most potent observation was not statistical. On the podcast, he noted — according to the Telegram posts that amplified the clip — that 95 percent of people in his large audiences know someone on antidepressants who is still depressed. This is not a research finding; it is an anecdote. But it reframes the abstract debate as lived experience, and the resonance it generated online reflects something genuine: the gap between what antidepressants are prescribed to do and what a substantial portion of users report experiencing.

The Robbins framing maps onto a real tension in clinical practice. Prescribing rates for antidepressants have risen steadily in the United States, United Kingdom, and across Western Europe over three decades. The increase tracks with expanded diagnostic criteria, direct-to-consumer pharmaceutical marketing, and a medical culture that has gradually normalised long-term SSRI use for chronic mild-to-moderate depression. It is precisely this expanded population — not the severe-depression patients in clinical trials — where the evidence for drug benefit is weakest and where Robbins' audience clearly recognised themselves.

What this moment means for treatment and research

The conversation that Robbins catalysed is not his alone. It reflects a slow, cautious recalibration within mainstream psychiatry about how to communicate SSRI efficacy. Peer-reviewed literature and prescribing guidelines have gradually moved toward more honest descriptions of what these drugs can and cannot do. The JAMA review did not advocate abandoning antidepressants. It advocated clear communication about realistic expectations, particularly for patients with mild symptoms who represent a large share of the prescribing surge.

For clinicians, the practical implication is straightforward: clearer conversations with patients about what benefit to expect, for how long, and what to do if that benefit does not materialise. For patients who have taken SSRIs and felt their benefit was limited, it means not framing the experience as personal failure. For researchers, it means continued investment in understanding depression neurobiology and funding for comparative effectiveness research that can identify which patients benefit most from which interventions.

The Telegram thread that brought this conversation to wide public attention captured something genuine about the current moment in psychiatric medicine: the public is ahead of the institutional conversation in acknowledging uncertainty. What looks like growing skepticism toward antidepressants is, more precisely, a growing appetite for honest accounting. That appetite is not going away, and the research community will eventually have to keep pace with it.

Monexus published this story after it circulated across Telegram channels in the week of 16 May 2026. The Robbins segment provided a hook for a much larger public conversation about antidepressant science that mainstream outlets had largely treated as settled. Monexus attempted to ground the cultural debate in its empirical dimensions — what the major reviews show, what they do not, and where the evidence genuinely remains contested.